Bionova Scientific Opens pDNA Development & Production Facility in Texas

Bionova Scientific, a full-service biologics contract development and manufacturing organization (CDMO) and subsidiary of Asahi Kasei, has opened a 10,000-square-foot plasmid DNA (pDNA) development and production facility in The Woodlands, Texas.

Located less than 30 miles north of Houston, Texas, the new facility designs, develops and manufactures research-grade pDNA materials to support the cell and gene therapy field. Enabled by the new facility, the company will expand its offerings beyond mammalian protein production and provide clinical to commercial-scale Current Good Manufacturing Practice (CGMP) production of pDNA by Q4 2025.

Adding pDNA development and manufacturing services enhances Bionova Scientific’s expertise in antibody and protein CDMO services. Through these added services, Bionova is broadening its portfolio across biotherapeutic modalities to serve more customers.

“Bionova added these highly sought-after pDNA capabilities in response to a persistent unmet need among the cell and gene therapy biopharma community. Completing this specialized facility on schedule is not only a milestone for our team, but a crucial step in ensuring our customers receive the reliable, timely support they need to meet their own deadlines,” commented Darren Head, President and Chair of Bionova.

Bionova chose The Woodlands because of its proximity to a growing number of CGT companies. Furthermore, its location provides Bionova with access to the rapidly expanding CGT ecosystem in the U.S.

More Bionova News

Earlier this year, Bionova opened a 55,000 sq. ft. process development and pilot plant in Fremont, California.